Isavuconazole treatment of invasive fungal sinusitis: a post hoc analysis of the SECURE and VITAL trials
Clin Infect Dis. 2021 Apr 29:ciab386. doi: 10.1093/cid/ciab386. Online ahead of print.
This post-hoc analysis of international phase III isavuconazole trials identified 50 patients (90% immunocompromised or diabetic) with invasive fungal sinusitis (88% mucormycetes, Aspergillus) who received isavuconazole as primary (33) or salvage (17) therapy for median 82 days (range 2-882). Overall survival was 82% at day 42, 70% at day 84.